An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis

Cytokine

Volumn 67, Issue 2, 2014, Pages 65-70

  Demyanets, Svitlana ^a   Tentzeris, Ioannis ^b   Jarai, Rudolf ^b   Katsaros, Katharina M ^a,c   Farhan, Serdar ^b   Wonnerth, Anna ^a   Weiss, Thomas W ^b   Wojta, Johann ^a,c   Speidl, Walter S ^a   Huber, Kurt ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Coronary artery disease; Interleukin 33; Myocardial infarction; Percutaneous coronary intervention; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD SAMPLING; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY STENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; IN-STENT RESTENOSIS; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; AGED; ANGINA, STABLE; BLOOD; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; HEART DISEASES; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROCEDURES; STATISTICAL MODEL; STENT;

AGED; ANGINA, STABLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; HEART DISEASES; HUMANS; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; STENTS;

EID: 84896941101     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.02.014     Document Type: Article

References (43)

1. Jukema J.W., Verschuren J.J., Ahmed T.A., Quax P.H. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012, 9:53-62.
2. Niccoli G., Montone R.A., Ferrante G., Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010, 56:1783-1793.
3. Inoue T., Croce K., Morooka T., Sakuma M., Node K., Simon D.I. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. J Am Coll Cardiol Intv 2011, 4:1057-1066.
4. Welt F.G., Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002, 22:1769-1776.
5. Speidl W.S., Katsaros K.M., Kastl S.P., Zorn G., Huber K., Maurer G., et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010, 208:285-289.
6. Monraats P.S., Pires N.M., Schepers A., Agema W.R., Boesten L.S., de Vries M.R., et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005, 19:1998-2004.
7. Rudolph T., Schaps K.P., Steven D., Koester R., Rudolph V., Berger J., et al. Interleukin-3 is elevated in patients with coronary artery disease and predicts restenosis after percutaneous coronary intervention. Int J Cardiol 2009, 132:392-397.
8. Jones G.T., Kay I.P., Chu J.W., Wilkins G.T., Phillips L.V., McCormick M., et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006, 26:e121-e125.
9. Katsaros K.M., Kastl S.P., Zorn G., Maurer G., Wojta J., Huber K., et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. J Am Coll Cardiol Intv 2010, 3:90-97.
10. Christ G., Nikfardjam M., Huber-Beckmann R., Gottsauner-Wolf M., Glogar D., Binder B.R., et al. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J Thromb Haemost 2005, 3:233-239.
11. Katsaros K.M., Speidl W.S., Kastl S.P., Zorn G., Huber K., Maurer G., et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008, 6:508-513.
12. Katsaros K.M., Wiesbauer F., Speidl W.S., Kastl S.P., Huber K., Zorn G., et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost 2011, 105:883-891.
13. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
14. Demyanets S., Kaun C., Pentz R., Krychtiuk K.A., Rauscher S., Pfaffenberger S., et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013, 60:16-26.
15. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS One 2008, 3:e3331.
16. Liew F.Y. IL-33: a Janus cytokine. Ann Rheum Dis 2012, 71(2):i101-i104.
17. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009, 106:9021-9026.
18. Luthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84-98.
19. Eiwegger T., Akdis C.A. IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol 2011, 41:1535-1538.
20. Zheng Y., Gardner S.E., Clarke M.C. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2011, 31:2781-2786.
21. Miller A.M. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8:22.
22. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
23. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
24. Dhillon O.S., Narayan H.K., Khan S.Q., Kelly D., Quinn P.A., Squire I.B., et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?. Int J Cardiol 2013, 167:2182-2188.
25. Dhillon O.S., Narayan H.K., Quinn P.A., Squire I.B., Davies J.E., Ng L.L. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with global registry of acute coronary events risk scoring and NT-proBNP. Am Heart J 2011, 161:1163-1170.
26. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11:116-128.
27. Szkodzinski J., Blazelonis A., Wilczek K., Hudzik B., Romanowski W., Gasior M., et al. The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol 2009, 22:493-500.
28. Zurakowski A., Wojakowski W., Dzielski T., Milewski K., Goscinska-Bis K., Tendera M., et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol Pol 2009, 67:623-630.
29. Smithgall M.D., Comeau M.R., Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
30. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009, 183:1446-1455.
31. Rittersma S.Z., Meuwissen M., van der Loos C.M., Koch K.T., de Winter R.J., Piek J.J., et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 2006, 184:157-162.
32. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
33. Bot I., Biessen E.A. Mast cells in atherosclerosis. Thromb Haemost 2011, 106:820-826.
34. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
35. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
36. Demyanets S., Konya V., Kastl S.P., Kaun C., Rauscher S., Niessner A., et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011, 31:2080-2089.
37. Aoki S., Hayakawa M., Ozaki H., Takezako N., Obata H., Ibaraki N., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010, 335:75-81.
38. Moreno P.R., Purushothaman K.R., Zias E., Sanz J., Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med 2006, 6:457-477.
39. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
40. Saxena A., Rauch U., Berg K.E., Andersson L., Hollender L., Carlsson A.M., et al. The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling. Cardiovasc Res 2011, 91:350-357.
41. Ishikawa S., Shimizu M., Ueno K., Sugimoto N., Yachie A. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine 2013, 62:272-277.
42. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011, 30:825-830.
43. Pastorelli L., Garg R.R., Hoang S.B., Spina L., Mattioli B., Scarpa M., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010, 107:8017-8022.